It is the technology responsible for the use of living organisms or compounds obtained from these to obtain products valuable to mankind.

Its history goes back several years with the manufacture of bread, wine, cheese, yoghurt and beer. However, with the discovery of the DNA structure by Watson and Crick in 1953, the term "Modern Biotechnology" emerged, defined as the commercial application of living organisms or their products, which involves the deliberate manipulation of their DNA molecules.

Landsteiner Scientific focuses on research, development, production and commercialization of biotechnological drug products for human use, in order to strengthen and improve existing therapeutic tools. These high specificity drug products are able to cure diseases that years ago had no cure or significantly improve the life quality of those people who have illnesses yet without treatment.

Landsteiner Scientific focuses on research, development, production and commercialization of biotechnological drug products for human use, in order to strengthen and improve existing therapeutic tools. These high specificity drug products are able to cure diseases that years ago had no cure or significantly improve the life quality of those people who have illnesses yet without treatment.

In Landsteiner Scientific, biotech research, has added to its main objectives the development of a group of molecules very limited in Mexico so far: "Monoclonal Antibodies.” To achieve this challenge, we have established agreements with well-known University Centers and technology providers who share the spotlight of this research. We endeavor to ensure the Academy-Company relationship, under a collaboration scheme focused on covering the main needs of development of this cutting-edge branch in the country.

Biotechnology Proyects

Development of Recombinant DNA Technologies Towards the Manufacture of Biomedicines Against Chronic-degenerative Diseases.

Processes for the production of therapeutic recombinant proteins, which form the basis of the manufacturing process of high speciality biocomparable drugs, are developed from genetic engineering techniques.

Scaling of biotechnological processes for the manufacture of biocomparable drug products for the treatment of autoimmune diseases and cancer.

Optimization of pharmaceutical production procedures and analytical methods (manufacture of biocomparable drug products batches and their comparative characterization against reference drug products) from the existing ones at laboratory scale to industrial scale, integrating the workflow in the context of good manufacturing practices (GMPs) of biological drugs.